文献速递贫血与红细胞疾病

血红蛋白巴特胎儿水肿综合征幸存者国际登记研究

An international registry of survivors with Hb Bart's hydrops fetalis syndrome.
PubMed 文献 · Blood · 2017-01-05

该研究建立了一个包含69例血红蛋白巴特胎儿水肿综合征(BHFS)患者的国际登记库,其中31例为既往未发表病例。分析显示,39例存活超过5岁,18例超过10岁;宫内治疗可能对围产期和新生儿期有益,但对长期生长和神经发育可能无额外获益。约40%存在严重体重落后,约50%存在严重身高落后,20%(11/55)存在≥6个月的严重神经发育延迟,多数患者需终身输血。

要点

  • BHFS不再普遍致死,登记库中39例存活超过5岁,18例超过10岁。
  • 宫内治疗可能对围产期和新生儿期有益,但对长期生长和神经发育可能无额外获益。
  • 约40%严重体重落后、约50%严重身高落后,20%(11/55)有≥6个月严重神经发育延迟。

核心结论

  • 基于现有病例,有证据提示宫内治疗对围产期和新生儿期有益,但可能对长期生长和神经发育无额外获益。
  • 生长迟缓是BHFS患者主要的长期不良结局,约40%体重严重受影响、约50%身高严重受影响。
  • BHFS幸存者神经发育延迟风险增加,20%(11/55)存在≥6个月的严重延迟。
  • 登记库中多数患者需终身输血,并常合并先天性异常和合并症。

研究设计与样本

  • 建立了一个包含69例血红蛋白巴特胎儿水肿综合征患者的国际登记库,其中31例为既往未发表病例。
  • 基于登记库中可获得的临床信息进行分析,以记录BHFS的自然史。

主要发现

  • 69例患者中,39例存活超过5岁,其中18例目前超过10岁。
  • 约40%的BHFS患者体重严重受影响,约50%身高严重受影响。
  • 20%(11/55)的BHFS幸存者存在≥6个月的严重神经发育延迟。
  • 登记库中多数患者需终身输血,并常合并先天性异常和合并症。

临床怎么用

  • 作者指出,未来积累足够病例后,计划在本研究基础上提供信息,以便对高危夫妇进行咨询。
  • 作者认为本报告是收集信息的第一步,旨在为受影响婴儿的预测结局提供知情咨询。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemoglobin (Hb) Bart's hydrops fetalis syndrome (BHFS) resulting from α0-thalassemia is considered a universally fatal disorder. However, over the last 3 decades, improvements in intrauterine interventions and perinatal intensive care have resulted in increasing numbers of BHFS survivors. We have initiated an international registry containing information on 69 patients, of which 31 are previously unpublished. In this perspective, we analyze the available clinical information to document the natural history of BHFS. In the future, once we have accrued sufficient cases, we aim to build on this study and provide information to allow counseling of at-risk couples. To date, 39 patients have survived beyond the age of 5 years, 18 of whom are now older than 10 years. Based on the available cases, we find evidence to suggest that intrauterine therapy provides benefits during the perinatal and neonatal period; however, it may not provide additional benefits to long-term growth and neurodevelopmental outcomes. Growth retardation is a major adverse long-term outcome among BHFS patients with ∼40% being severely affected in terms of weight and ∼50% in terms of height. There is also an increased risk of neurodevelopmental delay as we find 20% (11/55) of BHFS survivors suffer from a serious delay of ≥6 months. Most patients in the registry require lifelong transfusion and often have associated congenital abnormalities and comorbidities. This perspective is a first step in gathering information to allow provision of informed counseling on the predicted outcomes of affected babies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Songdej D, Babbs C, Higgs DR, et al. An international registry of survivors with Hb Bart's hydrops fetalis syndrome. Blood. 2017. PMID: 28057638. doi:10.1182/blood-2016-08-697110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。